X4 Pharmaceuticals Inc

Overview

Discover mavorixafor, our innovative CXCR4 antagonist offering new hope for individuals with chronic neutropenic disorders. Learn about our commitment to advancing treatments for rare immune system diseases and our groundbreaking clinical trials, including the Phase 3 4WARD trial for mavorixafor, now approved in the US for WHIM syndrome and exploring broader applications. Join us in transforming the landscape of therapeutic options for patients with high unmet medical needs.

Classification

This U.S. industry comprises establishments primarily engaged in manufacturing in-vivo diagnostic substances and pharmaceutical preparations (except biological) intended for internal and external consumption in dose forms, such as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.

1. Manufacturing32
2. Chemical Manufacturing325
3. Pharmaceutical and Medicine Manufacturing32541
4. Pharmaceutical Preparation Manufacturing325412

Capabilities

Federal awards